Form 4: Vigil Neuroscience Director Bruhn Receives Stock Option Award

Suzanne Louise Bruhn, a director at Vigil Neuroscience, Inc., was granted a stock option award for 33,875 shares on March 3, 2025.

Summary

• Suzanne Louise Bruhn, a director at Vigil Neuroscience, Inc., received a stock option award on March 3, 2025.
• The award is for 33,875 shares of common stock.
• The exercise price of the stock options is $2.19.
• The options vest in four equal quarterly installments, starting March 31, 2025, and expire on March 3, 2035.
• The stock option award was issued in lieu of cash compensation under the Issuer's Non-Employee Director Compensation Policy.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard compensation practice, indicating confidence in the company's future.

Positives

• The stock option award aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service on the board.

Industry Context

Stock option awards are a common form of compensation for directors, aligning their interests with the long-term success of the company. This is a standard practice in the biotechnology industry to attract and retain qualified board members.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a common practice across the biotechnology industry.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize equity-based compensation for their board members.
• The size of the grant is typical for a company of Vigil Neuroscience's size and stage of development.

Stakeholder Impact

• The stock option award could have a slightly dilutive effect on existing shareholders.
• The award incentivizes the director to act in the best interests of the shareholders.

Key Dates